Novo Nordisk Weight Loss Drug
- All
- News
- Videos
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
Abbott, Novo Nordisk India Partner Up To Launch Second Brand Of Ozempic, Widen Access To Diabetes Drug
Abbott has entered into a commercialisation agreement with Novo Nordisk India to market a second brand of semaglutide, Extensior, in India
-
Novo Nordisk's CagriSema Delivers 23% Weight Loss In Trial But Still Trails Eli Lilly's Tirzepatide
CagriSema is a once-weekly subcutaneous injection, which is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity.
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
Weight Loss Pill Wegovy Now Available On Amazon Pharmacy In The U.S.
Amazon Pharmacy maintains the requirement for a valid prescription as the central safeguard separating evidence-based medical therapy from consumer health products.
-
Diabetes, Weight Loss Drug Ozempic Launched In India: See Dosage, Price And More
Novo Nordisk on Friday launched its blockbuster weight-loss drug Ozempic in India, beginning at Rs 8,800 a month or four weeks.
-
Ozempic, Type 2 Diabetes, Weight Loss Drug Launched In India. Check Price
Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming diabetes and obesity market expected to power industry growth this decade.
-
Novo Nordisk Partners With Emcure To Launch Weight Loss Drug Poviztra In India
Emcure Pharma becomes the first Indian company to hold exclusive rights to distribute and commercialise Poviztra, a semaglutide injection 2.4 mg for weight loss, the statement said.
-
Weight-Loss Breakthrough: Drug Cuts Heart Risk Even If You Don't Shed Kilos
A large-scale study shows semaglutide reduces heart risks regardless of weight loss, suggesting the drug benefits cardiovascular health in more ways than previously thought. The findings highlight waist size as a stronger indicator of heart improveme
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
Abbott, Novo Nordisk India Partner Up To Launch Second Brand Of Ozempic, Widen Access To Diabetes Drug
Abbott has entered into a commercialisation agreement with Novo Nordisk India to market a second brand of semaglutide, Extensior, in India
-
Novo Nordisk's CagriSema Delivers 23% Weight Loss In Trial But Still Trails Eli Lilly's Tirzepatide
CagriSema is a once-weekly subcutaneous injection, which is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity.
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
Weight Loss Pill Wegovy Now Available On Amazon Pharmacy In The U.S.
Amazon Pharmacy maintains the requirement for a valid prescription as the central safeguard separating evidence-based medical therapy from consumer health products.
-
Diabetes, Weight Loss Drug Ozempic Launched In India: See Dosage, Price And More
Novo Nordisk on Friday launched its blockbuster weight-loss drug Ozempic in India, beginning at Rs 8,800 a month or four weeks.
-
Ozempic, Type 2 Diabetes, Weight Loss Drug Launched In India. Check Price
Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming diabetes and obesity market expected to power industry growth this decade.
-
Novo Nordisk Partners With Emcure To Launch Weight Loss Drug Poviztra In India
Emcure Pharma becomes the first Indian company to hold exclusive rights to distribute and commercialise Poviztra, a semaglutide injection 2.4 mg for weight loss, the statement said.
-
Weight-Loss Breakthrough: Drug Cuts Heart Risk Even If You Don't Shed Kilos
A large-scale study shows semaglutide reduces heart risks regardless of weight loss, suggesting the drug benefits cardiovascular health in more ways than previously thought. The findings highlight waist size as a stronger indicator of heart improveme
